Malmö, Sweden
Malmö, Sweden

Time filter

Source Type

News Article | April 24, 2017
Site: www.businesswire.com

GOETTINGEN, Germany--(BUSINESS WIRE)--Sartorius (FWB:SRT), a leading international partner of the biopharmaceutical industry and research laboratories, increased its sales revenue and earnings in the first quarter of 2017 by double digits. "Both divisions successfully started off the current year. Lab Products & Services achieved considerable organic growth, and with the acquisition of Essen BioScience, it added another innovative product family to its bioanalytics portfolio and further growth potential,” said CEO and Executive Board Chairman Dr. Joachim Kreuzburg. The substantially above-average market growth for Bioprocess Solutions over the past two years has returned to normal rates, as expected. "In particular, business development in the Americas region was somewhat more moderate in the first quarter; however, we expect demand to pick up over the year," emphasized Kreuzburg. Management confirms its guidance raised at the beginning of April due to consolidation of its acquisitions: sales for the full year are projected to grow by about 12% to 16% and the company's earnings margin1 is forecasted to increase by slightly more than 0.5 percentage points. In the first three months of 2017, Sartorius increased its sales revenue in constant currencies by 12.2% (reported +13.6%) from 301.9 million euros in the year-earlier period to 343.1 million euros. The Asia|Pacific region recorded the strongest growth, with sales up 33.3% to 80.0 million euros. Both Group divisions contributed double-digit gains to this development. In the EMEA2 region, Sartorius generated sales of 151.2 million euros, 8.9% more than in the comparable year-earlier period. First-quarter sales revenue for the Americas region was 111.9 million euros, up 4.9% from a year ago. (All regional figures in constant currencies) Earnings in the reporting period rose overproportionately again relative to sales. Sartorius thus increased its underlying EBITDA by 17.0% to 84.6 million euros, and its respective margin from 24.0% to 24.7%. Relevant net profit3 for the Group grew by 17.7% from 29.3 million euros to 34.4 million euros. Earnings per ordinary share totaled 0.50 euros (Q1 2016: 0.42 euros4) and earnings per preference share 0.51 euros (Q1 2016: 0.43 euros4). The Group's key financial indicators remained at very robust levels following its most recent acquisition of Essen BioScience. At the end of the reporting period, the ratio of net debt to underlying EBITDA stood at 2.4 and company's equity ratio was 34.2% (Dec. 31, 2016: 1.5 and 42.0%, resp.). At 12.8%, the capex ratio in the first quarter was within the range expected. The Bioprocess Solutions Division, which offers a broad range of innovative technologies for the manufacture of biopharmaceuticals, recorded first-quarter sales growth of 9.4% in constant currencies to 251.1 million euros. Following two years of strong above-average dynamics, market growth in this segment returned to normal rates, as expected. In particular, the development in the Americas region was influenced at the beginning of the year by softer customer demand as well as by temporarily limited delivery capacities for cell culture media. The division increased its underlying EBITDA overproportionately again with respect to sales, by 12.1% to 68.4 million euros; its margin reached 27.2% relative to 26.9% in the comparable year-earlier period. The acquisition of the software company Umetrics closed at the beginning of April 2017 did not have any effect in the first quarter. The Lab Products & Services Division, which offers technologies for laboratories, primarily for the pharma sector and public research, significantly increased sales revenue in the first three months of the current year by 21.0% to 92.0 million euros (reported +22.7%). Based on strong demand in all regions and for all product segments, the division reported organic growth of around 10%. Altogether, around 11 percentage points of the division’s growth were contributed by portfolio expansion in the area of bioanalytics due to the acquisitions of IntelliCyt and ViroCyt in mid-2016, as well as Essen BioScience at the end of March 2017. Driven by economies of scale related to strong organic growth and acquisitions, the division's underlying EBITDA rose sharply by 43.1% to 16.3 million euros; its respective earnings margin improved from 15.2% to 17.7%. The Sartorius Group confirms its guidance for the current year, which it raised on April 3, 2017, due to its most recent acquisitions of Essen BioScience and Umetrics. Management thus projects that Group sales revenue for the full year will grow by about 12% to 16% and underlying EBITDA margin will increase slightly more than by half a percentage point over the prior-year figure of 25.0%. Regarding the two divisions, management anticipates that sales for Bioprocess Solutions will grow by about 9% to 13% and that the division's underlying EBITDA margin will rise by around half a percentage point (prior-year figure: 28.0%). For the Lab Products & Services Division, Group management projects that, assuming an overall stable economic environment, sales will increase by about 20% to 24% and the division's underlying EBITDA margin will rise by nearly two percentage points compared with the prior-year figure of 16.0%. (All forecasts are based on constant currencies) The capex ratio for the current fiscal year is projected to remain at around 12% to 15%. The ratio of net debt to underlying EBITDA at year-end is expected to remain about at the current level of 2.4 (Dec. 31, 2016: 1.5) as a result of the company's most recent acquisitions. Any further acquisitions have not been considered in these projections. 1 Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization; adjusted for extraordinary items) as the key profitability indicator 2 EMEA = Europe | Middle East | Africa 3 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects. 4 Adjusted for stock split; rounded values This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. Sartorius products used in the manufacture of medications www.sartorius.com/mediafile/corp/Sartorius_0232_PG9_01_RGB.jpg Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the company's results with analysts and investors on Monday, April 24, 2017, at 3:30 p.m. Central European Time (CET) in a teleconference. You may register by clicking on the following link: http://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=2173934&linkSecurityString=8938b98a Alternatively, you can dial into the teleconference, without registering, at: +49 (0) 69 566 03 6000 July 25, 2017 Publication of the first-half figures (January to June 2017) The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. More than 6,900 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe. Key Performance Indicators for the first quarter of 2017


Czolkos I.,Technical University of Denmark | Dock E.,Akzo Nobel | Tonning E.,Fiberline Composites A S | Christensen J.,Umetrics AB | And 8 more authors.
Biosensors and Bioelectronics | Year: 2016

Wastewater samples from a Swedish chemi-thermo-mechanical pulp (CTMP) mill collected at different purification stages in a wastewater treatment plant (WWTP) were analyzed with an amperometric enzyme-based biosensor array in a flow-injection system. In order to resolve the complex composition of the wastewater, the array consists of several sensing elements which yield a multidimensional response. We used principal component analysis (PCA) to decompose the array's responses, and found that wastewater with different degrees of pollution can be differentiated. With the help of partial least squares regression (PLS-R), we could link the sensor responses to the Microtox® toxicity parameter, as well as to global organic pollution parameters (COD, BOD, and TOC). From investigating the influences of individual sensors in the array, it was found that the best models were in most cases obtained when all sensors in the array were included in the PLS-R model. We find that fast simultaneous determination of several global environmental parameters characterizing wastewaters is possible with this kind of biosensor array, in particular because of the link between the sensor responses and the biological effect onto the ecosystem into which the wastewater would be released. In conjunction with multivariate data analysis tools, there is strong potential to reduce the total time until a result is yielded from days to a few minutes. © 2015 Elsevier B.V.


PubMed | AnoxKaldnes AB, Copenhagen University, Masaryk University, DHI Water - Environment - Health and 7 more.
Type: | Journal: Biosensors & bioelectronics | Year: 2015

Wastewater samples from a Swedish chemi-thermo-mechanical pulp (CTMP) mill collected at different purification stages in a wastewater treatment plant (WWTP) were analyzed with an amperometric enzyme-based biosensor array in a flow-injection system. In order to resolve the complex composition of the wastewater, the array consists of several sensing elements which yield a multidimensional response. We used principal component analysis (PCA) to decompose the arrays responses, and found that wastewater with different degrees of pollution can be differentiated. With the help of partial least squares regression (PLS-R), we could link the sensor responses to the Microtox toxicity parameter, as well as to global organic pollution parameters (COD, BOD, and TOC). From investigating the influences of individual sensors in the array, it was found that the best models were in most cases obtained when all sensors in the array were included in the PLS-R model. We find that fast simultaneous determination of several global environmental parameters characterizing wastewaters is possible with this kind of biosensor array, in particular because of the link between the sensor responses and the biological effect onto the ecosystem into which the wastewater would be released. In conjunction with multivariate data analysis tools, there is strong potential to reduce the total time until a result is yielded from days to a few minutes.


News Article | November 15, 2016
Site: globenewswire.com

ANDOVER, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- MKS Instruments, Inc. (NASDAQ:MKSI), a global provider of technologies that enable advanced processes and improve productivity, today announced the release of Easy Analytics, part of the Umetrics Suite of Data Analytics Solutions.  Easy Analytics is an easy to use, stand-alone, solution that imports, organizes and analyzes process and quality data. Easy Analytics has been designed for simplicity of use and clarity of results which can help users to analyze and process their data without being a data scientist or expert. In one click, users can import data to standardized or customized reports of quality and process status. By reducing the number of clicks required Easy Analytics minimizes the risk of errors and facilitates process status communication. In addition to the standard functionality of Easy Analytics, a toolbox containing Western electric rules and Capability analysis will also be released. The toolbox enables excellent data visualization and deviation quantification, and makes it possible for the process engineer and development scientist to see situations in data that don’t behave as expected. Easy Analytics can be directly connected to SIMCA® Multivariate Data Analysis Solution, for a deeper analysis of identified issues. About MKS Data Analytics Solutions MKS Data Analytics Solutions are leading data analytics experts with multiple applications in high-tech industries worldwide. We enable customers at both the individual and enterprise levels to maximize the value of their data, enabling better decision-making and process excellence. To learn more about how MKS Data Analytics Solutions can help you grow your business please visit www.mksdataanalytics.com. About MKS Instruments MKS Instruments, Inc. is a global provider of instruments, subsystems and process control solutions that measure, control, power, monitor, and analyze critical parameters of advanced manufacturing processes to improve process performance and productivity. Our products are derived from our core competencies in pressure measurement and control, materials delivery, gas composition analysis, control and information technology, power and reactive gas generation, vacuum technology, photonics, lasers, optics and motion control. Our primary served markets include semiconductor capital equipment, industrial manufacturing, environmental, medical, life sciences and scientific research. Additional information can be found at www.mksinst.com.


Euerby M.R.,Hichrom Ltd | James M.,Hichrom Ltd | Axelsson B.-O.,Novo Nordisk AS | Rosen O.,Umetrics AB | Petersson P.,Novo Nordisk AS
Journal of Separation Science | Year: 2012

The validity of the extended Tanaka column characterization procedure against the retention behavior of 101 analytes of widely differing properties chromatographed on five differing stationary phase chemistries has been established using a chemometric technique called principal component analysis (PCA). It was concluded that the simple and conveniently determined column characterization parameters covered the same space in the PCA loading plot as the retention times for the 101 differing analytes. This confirms that the ten column characterization parameters of the extended Tanaka protocol encode the same information as the retention times of the 101 analytes. Significant selectivity differences were observed between stationary phases and the mobile-phase modifiers - MeOH and MeCN. PCA contribution plots served as a convenient way to highlight specific selectivity differences between stationary phases. logD values exhibited a poor correlation with retention indicating that retention in RP-LC is not solely dictated by the analyte's hydrophobicity. The use of MeOH was found to generate greater selectivity differences with the five stationary phases than when MeCN is used. © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Eliasson M.,Umeå University | Rannar S.,Umeå University | Madsen R.,Umeå University | Donten M.A.,Umeå University | And 6 more authors.
Analytical Chemistry | Year: 2012

A strategy for optimizing LC-MS metabolomics data processing is proposed. We applied this strategy on the XCMS open source package written in R on both human and plant biology data. The strategy is a sequential design of experiments (DoE) based on a dilution series from a pooled sample and a measure of correlation between diluted concentrations and integrated peak areas. The reliability index metric, used to define peak quality, simultaneously favors reliable peaks and disfavors unreliable peaks using a weighted ratio between peaks with high and low response linearity. DoE optimization resulted in the case studies in more than 57% improvement in the reliability index compared to the use of the default settings. The proposed strategy can be applied to any other data processing software involving parameters to be tuned, e.g., MZmine 2. It can also be fully automated and used as a module in a complete metabolomics data processing pipeline. © 2012 American Chemical Society.


Pinto R.C.,Umeå University | Stenlund H.,Umeå University | Hertzberg M.,SweTree Technologies AB | Lundstedt T.,AcureOmics AB | And 2 more authors.
Analytica Chimica Acta | Year: 2011

To find and ascertain phenotypic differences, minimal variation between biological replicates is always desired. Variation between the replicates can originate from genetic transformation but also from environmental effects in the greenhouse. Design of experiments (DoE) has been used in field trials for many years and proven its value but is underused within functional genomics including greenhouse experiments. We propose a strategy to estimate the effect of environmental factors with the ultimate goal of minimizing variation between biological replicates, based on DoE. DoE can be analyzed in many ways. We present a graphical solution together with solutions based on classical statistics as well as the newly developed OPLS methodology. In this study, we used DoE to evaluate the influence of plant specific factors (plant size, shoot type, plant quality, and amount of fertilizer) and rotation of plant positions on height and section area of 135 cloned wild type poplar trees grown in the greenhouse. Statistical analysis revealed that plant position was the main contributor to variability among biological replicates and applying a plant rotation scheme could reduce this variation. © 2010 Elsevier B.V.


Gottfries J.,Astrazeneca | Eriksson L.,Umetrics AB
Molecular Diversity | Year: 2010

A new set of amino acid descriptor scales was recently introduced. The new scales relate to amino acid side chain (i) rigidity and (ii) flexibility. These two properties were found to be orthogonal to each other. In this study, (i) the understanding of their meaning is improved, (ii) their utility further corroborated, and (iii) the scope of their applicability is broadened. Notably, the rigidity and flexibility scales are benchmarked against previous amino acid description precedence and found to contribute (1) new information, and (2) direct interpretation. The suggested description extensions were tested using empirical data from peptide description and in quantitative structure-activity relationships (QSAR). © 2009 Springer Science+Business Media B.V.

Loading Umetrics AB collaborators
Loading Umetrics AB collaborators